Literature DB >> 27862122

Rising Cost of Cancer Pharmaceuticals: Cost Issues and Interventions to Control Costs.

Ashley E Glode1, Megan Brafford May2.   

Abstract

The rising cost of pharmaceuticals and, in particular, cancer drugs has made headline news in recent years. Several factors contribute to increasing costs and the burden this places on the health care system and patients. Some of these factors include costly cancer pharmaceutical research and development, longer clinical trials required to achieve drug approval, manufacturing costs for complex compounds, and the economic principles surrounding oncology drug pricing. Strategies to control costs have been proposed, and some have already been implemented to mitigate cancer drug costs such as the use of clinical treatment pathways and tools to facilitate cost discussions with patients. In this article, we briefly review some of the potential factors contributing to increasing cancer pharmaceutical costs and interventions to mitigate costs, and touch on the role of health care providers in addressing this important issue.
© 2016 Pharmacotherapy Publications, Inc.

Entities:  

Keywords:  ASCO value framework; NCCN evidence blocks; cancer; clinical pathways; cost; financial toxicity; medications; oncology; oncology pharmacist; pharmaceuticals

Mesh:

Substances:

Year:  2016        PMID: 27862122     DOI: 10.1002/phar.1867

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  9 in total

Review 1.  Financial toxicity and implications for cancer care in the era of molecular and immune therapies.

Authors:  George Tran; S Yousuf Zafar
Journal:  Ann Transl Med       Date:  2018-05

2.  Factors influencing prostate cancer treatment decisions for African American and white men.

Authors:  Brittaney-Belle E Gordon; Ramsankar Basak; William R Carpenter; Deborah Usinger; Paul A Godley; Ronald C Chen
Journal:  Cancer       Date:  2019-01-29       Impact factor: 6.860

3.  Patient Perceptions of Using Clinical Decision Support for Cancer Screening and Prevention: "I wouldn't have thought about getting screened without it."

Authors:  Daniel M Saman; Melissa L Harry; Laura A Freitag; Clayton I Allen; Patrick J O'Connor; JoAnn M Sperl-Hillen; Joseph A Bianco; Anjali R Truitt; Heidi L Ekstrom; Thomas E Elliott
Journal:  J Patient Cent Res Rev       Date:  2021-10-18

4.  Supporting Low-income Cancer Patients: Recommendations for the Public Financial Aid Program in the Republic of Korea.

Authors:  Hye Sook Min; Hyung Kook Yang; Keeho Park
Journal:  Cancer Res Treat       Date:  2017-11-15       Impact factor: 4.679

5.  The impact of pricing strategy on the costs of oral anti-cancer drugs.

Authors:  Judy Truong; Kelvin K W Chan; Helen Mai; Alexandra Chambers; Mona Sabharwal; Maureen E Trudeau; Matthew C Cheung
Journal:  Cancer Med       Date:  2019-05-27       Impact factor: 4.452

6.  Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma.

Authors:  Tim F Greten; Ghassan K Abou-Alfa; Ann-Lii Cheng; Austin G Duffy; Anthony B El-Khoueiry; Richard S Finn; Peter R Galle; Lipika Goyal; Aiwu Ruth He; Ahmed O Kaseb; Robin Kate Kelley; Riccardo Lencioni; Amaia Lujambio; Donna Mabry Hrones; David J Pinato; Bruno Sangro; Roberto I Troisi; Andrea Wilson Woods; Thomas Yau; Andrew X Zhu; Ignacio Melero
Journal:  J Immunother Cancer       Date:  2021-09       Impact factor: 13.751

7.  Impact of a New Cost-Effectiveness Threshold Implementation on Cancer Formulary Decisions in Jordan.

Authors:  Imad Treish; Abeer Al Rabayah; Saad Jaddoua; Haitham Tuffaha
Journal:  Pharmacoecon Open       Date:  2021-11-13

8.  Modeling the Ex Ante Clinical Real Option Value in an Innovative Therapeutic Area: ALK-Positive Non-Small-Cell Lung Cancer.

Authors:  Woojung Lee; William B Wong; Stacey Kowal; Louis P Garrison; David L Veenstra; Meng Li
Journal:  Pharmacoeconomics       Date:  2022-05-09       Impact factor: 4.558

9.  Survival, cost and added therapeutic benefit of drugs granted early access through the French temporary authorization for use program in solid tumors from 2009 to 2019.

Authors:  Fiona Y-V Pham; Emmanuelle Jacquet; Amina Taleb; Adrien Monard; Ghania Kerouani-Lafaye; Florence Turcry; Liora Brunel; Françoise Grudé; Isabelle Yoldjian; Isabelle Sainte-Marie; Lotfi Boudali; Jean-Yves Blay; Nicolas Albin
Journal:  Int J Cancer       Date:  2022-07-07       Impact factor: 7.316

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.